HIV JournalView

Top 10 HIV Clinical Developments of 2013

December 8, 2013

David Alain Wohl, M.D.

David Alain Wohl, M.D.

A wise person -- well, actually, my 9-year-old son -- pointed out to me the other day that nothing stays the same. Each moment, molecules shift, matter is transformed and time moves forward.

This insight from a young mind was front and center in my own head as I looked to the selection of this year's top HIV stories. Things change -- and sometimes even evolve -- and it was this progression from the status quo to the innovative that caught my attention when assembling this collection.

Therapies for HIV have worked wonders, but (arguably) better options have recently become available, and we are on the cusp of radical advances that may greatly impact how we treat this infection. Meanwhile, the news on the hepatitis C (HCV) front has been nothing short of ecstatic; 2013 served as a preface for what promises to be a new era in which curing HCV finally becomes realistic for millions -- if they can afford it.

It has been a long and storied march that got us to this point, and we should all feel proud to be part of it. Here's to looking at a year of big and small triumphs, and hoping for even greater success stories for our patients in the year to come. That is change we can all believe in.

Table of Contents

David Alain Wohl, M.D., is an associate professor of medicine in the Division of Infectious Diseases at the University of North Carolina and site leader of the University of North Carolina AIDS Clinical Trials Unit at Chapel Hill.

Copyright © 2013 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication HIV JournalView.


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.